Transcription factors, the tiny proteins that switch genes on or off in the nucleus of cells, are considered unreachable molecular targets for drugs attempting to treat medical conditions. Overcoming this challenge, researchers discovered a small molecular compound that successfully blocks a transcription factor and its pro-inflammatory and hyper-mucous activity in asthma. In a study, scientists tested a new compound they call RCM-1.